Source comparison
TB-500 Cardiac Repair Research: Model Comparison
Different cardiac injury models reveal distinct aspects of TB-500's regenerative mechanisms. The table below compares outcomes across four primary experimental paradigms used in peer-reviewed TB-500 cardiac repair research. Permanent coronary ligation (rat) 6
This comparison does not assign a generated winner or score.
- Different cardiac injury models reveal distinct aspects of TB-500's regenerative mechanisms. The table below compares outcomes across four primary experimental paradigms used in peer-reviewed TB-500 cardiac repair research.
- Permanent coronary ligation (rat)
- 6 mg/kg loading × 3 days, then 3 mg/kg 3×/week × 25 days
- Infarct size at day 28 (% of LV)
- 52% reduction (TB-500: 18.2% vs Control: 38.1%)
- Cardiomyocyte migration, reduced apoptosis
- Gold standard for infarct size measurement; most reproducible model
- Ischemia-reperfusion (mouse)
- 10 mg/kg immediately pre-reperfusion, then 5 mg/kg daily × 7 days
- Ejection fraction at day 28 (echocardiography)
- 41% improvement (TB-500: 48.3% vs Control: 34.2%)
- Reduced oxidative stress, preserved mitochondrial function
- Clinically relevant to STEMI with PCI; oxidative burst is primary injury mechanism
- Cryoinjury (porcine)
- 2 mg/kg intramyocardial at injury, then 1 mg/kg SC 2×/week × 4 weeks
- Capillary density in border zone (vessels/mm²)
- 46% increase (TB-500: 127 vs Control: 87)
- VEGF-independent angiogenesis, eNOS upregulation
- Large animal model closest to human physiology; surgical access allows direct injection
- Doxorubicin cardiotoxicity (rat)
- 4 mg/kg concurrent with doxorubicin, continued 3×/week × 6 weeks
- Cardiomyocyte apoptosis (TUNEL+ cells/field)
- 63% reduction (TB-500: 8.4 vs Control: 22.7)
- Calcium handling restoration, reduced ER stress
- Non-ischemic injury model; demonstrates TB-500 efficacy beyond infarction
- The permanent ligation model remains the benchmark for TB-500 cardiac repair research because it isolates regenerative mechanisms from reperfusion variables. Ischemia-reperfusion models better simulate clinical STEMI (ST-elevation myocardial infarction) scenarios where patients receive percutaneous coronary intervention, but introduce oxidative stress confounders. Cryoinjury models produce transmural scars without coronary occlusion, allowing vessel formation studies without ischemic variables. Doxorubicin cardiotoxicity models demonstrate TB-500's protective effects extend beyond ischemic injury to chemotherapy-induced cardiomyopathy, where the mechanism shifts from migration to calcium homeostasis preservation.